Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 Y220C||stomach cancer||predicted - sensitive||PC14586||Preclinical - Cell line xenograft||Actionable||In a preclinical study, PC14586 treatment reactivated Tp53 function, resulted in 80% tumor regression after 3 weeks in cell line xenograft models of gastric cancer harboring TP53 Y220C (AACR Annual Meeting Apr 2021, Session MS.LBA01, Abstract # LB006).||detail...|
|PubMed Id||Reference Title||Details|
|PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development||Full reference...|